#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?

Nov 15, 2021 Episode Page ↗
Overview

This AMA episode features Peter Attia and Bob Kaplan discussing GLP-1 agonists, a class of drugs for obesity, focusing on semaglutide (Ozempic). They delve into the physiology of these peptides, a remarkable New England Journal of Medicine study on semaglutide for weight loss, and compare its results to lifestyle interventions.

At a Glance
4 Insights
14m 19s Duration
5 Topics
3 Concepts

Deep Dive Analysis

Introduction to GLP-1 Agonists and Semaglutide Study

Background on the Incretin Effect

Understanding Insulin: Secretion and Function

Understanding Glucagon: Secretion and Function

Visualizing the Incretin Effect with Glucose Administration

Insulin

Insulin is a hormone secreted by beta cells in the pancreas. It signals muscle, fat, and liver cells to take up glucose and tells the liver to stop making glucose, acting as a signal of the fed state, particularly sensitive to carbohydrates.

Glucagon

Glucagon is a hormone produced by alpha cells of the pancreas that increases blood glucose by stimulating hepatic glucose production through glycogenolysis and gluconeogenesis. It also increases lipolysis and ketone production, having an antagonistic relationship with insulin.

Incretin Effect

The incretin effect describes the phenomenon where the insulin response to oral glucose administration is significantly greater than the insulin response to an equivalent intravenous glucose administration. This difference, also observed with glucagon attenuation, highlights the role of gut hormones in glucose regulation.

?
What are GLP-1 agonists?

GLP-1 agonists are a class of drugs, such as semaglutide (Ozempic), that are currently popular for treating obesity and mimic the actions of naturally occurring GLP-1 peptides.

?
What is insulin and what does it do?

Insulin is a hormone secreted by pancreatic beta cells that signals muscle, fat, and liver cells to take up glucose and tells the liver to stop making glucose, indicating a fed state.

?
What is glucagon and what does it do?

Glucagon is a hormone produced by pancreatic alpha cells that increases blood glucose by stimulating the liver to produce glucose (glycogenolysis and gluconeogenesis) and also increases fat breakdown and ketone production.

?
What is the incretin effect?

The incretin effect is the observation that oral glucose administration elicits a much larger insulin response (and greater glucagon attenuation) compared to an equivalent intravenous glucose administration, due to the release of gut hormones.

1. Seek Professional Medical Advice

Do not use podcast content as a substitute for professional medical advice, diagnosis, or treatment; always seek assistance from healthcare professionals for any medical conditions you have.

2. Embrace Technical Detail

To truly understand complex topics like how a drug works and if it’s for you, be prepared to engage with technical information, as this is the price one has to pay for true understanding.

3. Use Qualies to Filter Episodes

Utilize “The Qualies” (short podcasts released Tuesday-Friday) to highlight key questions and tactics from previous episodes, which helps filter and decide which full episodes to listen to in detail.

4. Watch Sneak Peeks

If you are not a subscriber, you can catch a sneak peek of the video content for episodes on YouTube.

GLP-1 agonists are the class of drugs that are all the rage right now when it comes to understanding treatments for obesity.

Peter Attia

This study... the results were quite frankly, out of this world.

Peter Attia

You can't really go deep on this paper without doing a little bit of background on what GLP-1 is, because of course, this drug is effectively just an analog of GLP-1.

Peter Attia

Insulin is a signal of the fed state. And it's particularly sensitive, of course, to carbohydrates.

Peter Attia
5%
Pancreas mass dedicated to endocrine function (alpha and beta cells) The majority of pancreatic mass is for exocrine, local digestive function.
60 minutes
Peak time for plasma glucose after oral glucose load Followed by a return to baseline by three hours.
90 minutes
Peak time for insulin after oral glucose administration Followed by a return to baseline in about three to four hours.